Explore the vast range of titles available.

\"Economic inequality affects everybody. No matter how rich or poor you are, economic inequality impacts every aspect of your life--the place where you live, the opportunities you experience, the healthcare you get, the education you receive. More Than Money breaks down why the rich seem to be getting richer while the rest of us are struggling to just get by. With vivid, energetic illustrations, the use of graphs and charts, and tips for how to investigate topics of interest, readers learn the most important issues and ideas in economics to better understand the consequences of inequality.\"-- Provided by publisher.

Single-solution-based optimization algorithms have gained little to no attention by the research community, unlike population-based approaches. This paper proposes a novel optimization algorithm, called Single Candidate Optimizer (SCO), that relies only on a single candidate solution throughout the whole optimization process. The proposed algorithm implements a unique set of equations to effectively update the position of the candidate solution. To balance exploration and exploitation, SCO is integrated with the two-phase strategy where the candidate solution updates its position differently in each phase. The effectiveness of the proposed approach is validated by testing it on thirty three classical benchmarking functions and four real-world engineering problems. SCO is compared with three well-known optimization algorithms, i.e., Particle Swarm Optimization, Grey Wolf Optimizer, and Gravitational Search Algorithm and with four recent high-performance algorithms: Equilibrium Optimizer, Archimedes Optimization Algorithm, Mayfly Algorithm, and Salp Swarm Algorithm. According to Friedman and Wilcoxon rank-sum tests, SCO can significantly outperform all other algorithms for the majority of the investigated problems. The results achieved by SCO motivates the design and development of new single-solution-based optimization algorithms to further improve the performance. The source code of SCO is publicly available at: https://uk.mathworks.com/matlabcentral/fileexchange/116100-single-candidate-optimizer .

The discovery of nearly 180-year-old cranial measurements in the archives of 19th century American physician and naturalist Samuel George Morton can address a lingering debate, begun in the late 20th century by paleontologist and historian of science Stephen Jay Gould, about the unconscious bias alleged in Morton's comparative data of brain size in human racial groups. Analysis of Morton's lost data and the records of his studies does not support Gould's arguments about Morton's biased data collection. However, historical contextualization of Morton with his scientific peers, especially German anatomist Friedrich Tiedemann, suggests that, while Morton's data may have been unbiased, his cranial race science was not. Tiedemann and Morton independently produced similar data about human brain size in different racial groups but analyzed and interpreted their nearly equivalent results in dramatically different ways: Tiedemann using them to argue for equality and the abolition of slavery, and Morton using them to entrench racial divisions and hierarchy. These differences draw attention to the epistemic limitations of data and the pervasive role of bias within the broader historical, social, and cultural context of science.

Diabetic retinopathy is a common and specific microvascular complication of diabetes, and remains the leading cause of preventable blindness in working-aged people. It is identified in a third of people with diabetes and associated with increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure. Optimum control of blood glucose, blood pressure, and possibly blood lipids remains the foundation for reduction of risk of retinopathy development and progression. Timely laser therapy is effective for preservation of sight in proliferative retinopathy and macular oedema, but its ability to reverse visual loss is poor. Vitrectomy surgery might occasionally be needed for advanced retinopathy. New therapies, such as intraocular injection of steroids and antivascular endothelial growth-factor agents, are less destructive to the retina than are older therapies, and could be useful in patients who respond poorly to conventional therapy. The outlook for future treatment modalities, such as inhibition of other angiogenic factors, regenerative therapy, and topical therapy, is promising.

Effective maintenance therapies after chemoradiotherapy for lung cancer are lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer immunotherapy tecemotide improves survival in patients with stage III unresectable non-small-cell lung cancer when given as maintenance therapy after chemoradiation. The phase 3 START trial was an international, randomised, double-blind trial that recruited patients with unresectable stage III non-small-cell lung cancer who had completed chemoradiotherapy within the 4–12 week window before randomisation and received confirmation of stable disease or objective response. Patients were stratified by stage (IIIA vs IIIB), response to chemoradiotherapy (stable disease vs objective response), delivery of chemoradiotherapy (concurrent vs sequential), and region using block randomisation, and were randomly assigned (2:1, double-blind) by a central interactive voice randomisation system to either tecemotide or placebo. Injections of tecemotide (806 μg lipopeptide) or placebo were given every week for 8 weeks, and then every 6 weeks until disease progression or withdrawal. Cyclophosphamide 300 mg/m2 (before tecemotide) or saline (before placebo) was given once before the first study drug administration. The primary endpoint was overall survival in a modified intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00409188. From Feb 22, 2007, to Nov 15, 2011, 1513 patients were randomly assigned (1006 to tecemotide and 507 to placebo). 274 patients were excluded from the primary analysis population as a result of a clinical hold, resulting in analysis of 829 patients in the tecemotide group and 410 in the placebo group in the modified intention-to-treat population. Median overall survival was 25·6 months (95% CI 22·5–29·2) with tecemotide versus 22·3 months (19·6–25·5) with placebo (adjusted HR 0·88, 0·75–1·03; p=0·123). In the patients who received previous concurrent chemoradiotherapy, median overall survival for the 538 (65%) of 829 patients assigned to tecemotide was 30·8 months (95% CI 25·6–36·8) compared with 20·6 months (17·4–23·9) for the 268 (65%) of 410 patients assigned to placebo (adjusted HR 0·78, 0·64–0·95; p=0·016). In patients who received previous sequential chemoradiotherapy, overall survival did not differ between the 291 (35%) patients in the tecemotide group and the 142 (35%) patients in the placebo group (19·4 months [95% CI 17·6–23·1] vs 24·6 months [18·8–33·0], respectively; adjusted HR 1·12, 0·87–1·44; p=0·38). Grade 3–4 adverse events seen with a greater than 2% frequency with tecemotide were dyspnoea (49 [5%] of 1024 patients in the tecemotide group vs 21 [4%] of 477 patients in the placebo group), metastases to central nervous system (29 [3%] vs 6 [1%]), and pneumonia (23 [2%] vs 12 [3%]). Serious adverse events with a greater than 2% frequency with tecemotide were pneumonia (30 [3%] in the tecemotide group vs 14 [3%] in the placebo group), dyspnoea (29 [3%] vs 13 [3%]), and metastases to central nervous system (32 [3%] vs 9 [2%]). Serious immune-related adverse events did not differ between groups. We found no significant difference in overall survival with the administration of tecemotide after chemoradiotherapy compared with placebo for all patients with unresectable stage III non-small-cell lung cancer. However, tecemotide might have a role for patients who initially receive concurrent chemoradiotherapy, and further study in this population is warranted. Merck KGaA (Darmstadt, Germany).

There is paucity of population-based data on occupational noise exposure and risk of age-related hearing loss. Therefore, we assessed cross-sectional and longitudinal associations of past workplace noise exposure with hearing loss in older adults. At baseline, 1923 participants aged 50+ years with audiological and occupational noise exposure data included for analysis. The pure-tone average of frequencies 0.5, 1.0, 2.0 and 4.0 kHz (PTA 0.5-4KHz ) >25 dB HL in the better ear, established the presence of hearing loss. Participants reported exposure to workplace noise, and the severity and duration of this exposure. Prior occupational noise exposure was associated with a 2-fold increased odds of moderate-to-severe hearing loss: multivariable-adjusted OR 2.35 (95% CI 1.45–3.79). Exposure to workplace noise for >10 years increased the odds of having any hearing loss (OR 2.39, 95% CI 1.37–4.19) and moderate-to-severe hearing loss (OR 6.80, 95% CI 2.97–15.60). Among participants reporting past workplace noise exposure at baseline the 10-year incidence of hearing loss was 35.5% versus 29.1% in those who had no workplace noise exposure. Workplace noise exposure was associated with a greater risk of incident hearing loss during the 10-year follow-up: multivariable-adjusted OR 1.39 (95% CI 1.13–1.71). Prior occupational noise exposure was not associated with hearing loss progression. Workplace noise exposure increased the risk of incident hearing loss in older adults. Our findings underscore the importance of preventive measures which diminish noise exposure in the workplace, which could potentially contribute towards reducing the burden of hearing loss in later life.

This article responds to the critical debate around Jennifer Kent’s horror movie, The Babadook (2014), by offering an analysis that moves beyond its use of generic codes and its sociopolitical representation of maternity. It contends that reading the film as a trauma narrative allows us to better understand the horrifying experience suffered by Amelia Vanek (Essie Davis): her husband’s premature death in a car accident. Taking Dominick LaCapra’s concepts of acting out and working through as key interpretive tools, the analysis demonstrates how Kent conveys posttraumatic stress disorder as both a visceral and a material experience, inscribing absence and loss onto the cinematic texture of the film. The article offers the conclusion that, as The Babadook enacts Amelia’s process of recuperation, figured as a psychosomatic struggle against her monstrous Other, she becomes able to express her trauma and, in doing so, is finally able to accept her husband’s death. Este artículo responde al debate crítico sobre la película de terror de Jennifer Kent, El Babadook (2014), ofreciendo un análisis que va más allá de su uso de códigos genéricos o la representación sociopolítica de la maternidad. El artículo argumenta que interpretar la película como una narrativa sobre el trauma nos permite entender mejor la horrible experiencia sufrida por Amelia Vanek (Essie Davis): el fallecimiento prematuro de su marido en un accidente de tráfico. Tomando los conceptos de Dominick LaCapra de acting out y working through como herramientas interpretativas clave, el análisis muestra la manera en que Kent caracteriza el síndrome del estrés postraumático como una experiencia tanto visceral como material, imprimiendo los conceptos de ausencia y pérdida en la textura cinematográfica de la película. El artículo ofrece como conclusión que, a medida que El Babadook recrea su proceso de recuperación, presentado como una lucha psicosomática contra un “otro yo” monstruoso, Amelia es capaz de expresar su trauma y, al hacerlo, finalmente logra aceptar la muerte de su marido.